

TiGenix Reacts to Rumors

Leuven, Belgium – 14 December 2012 – TiGenix NV (Euronext Brussels: TIG) announces that, apparently as a result of unauthorized access to certain non-public sections of TiGenix’s website, draft announcements regarding a potential capital increase by way of a private placement have surfaced today on certain internet forums. The company is still investigating the source and cause of this unauthorized access but has immediately alerted the FSMA to these facts. The FSMA has subsequently halted trading in the stock of the company awaiting this statement of TiGenix.

As is common in the biotech sector, the company regularly examines and prepares for opportunities to secure additional financing, including the possibility of a capital increase. However, TiGenix has not taken a decision to engage in such a transaction at this point in time. If and when such a transaction were to be decided, the company will inform the market in due course.

Contacts

Eduardo Bravo
Chief Executive Officer
eduardo.bravo@tigenix.com

Claudia D’Augusta
Chief Financial Officer
claudia.daugusta@tigenix.com

Hans Herklots
hans.herklots@tigenix.com
+32 16 39 60 97

About TiGenix

TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.

Forward-looking information

This document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond TiGenix’ control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to

TIGENIX

reflect any change in TiGenix' expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.